{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:49:11Z","timestamp":1792482551905,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,27]]},"DOI":"10.7759\/cureus.29652","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T15:12:49Z","timestamp":1664291569000},"source":"Crossref","is-referenced-by-count":16,"title":["A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis"],"prefix":"10.7759","author":[{"given":"Khyati","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"FDA. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2020). Accessed. 03-19-2020: http:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-a...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang KM","year":"2020","unstructured":"Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020, 2:218-21. 10.1016\/j.xkme.2019.12.006","journal-title":"Kidney Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu N","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015, 38:1680-6. 10.2337\/dc15-1251","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2018.02.025","article-title":"SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant","volume":"114","author":"Finucane FM","year":"2018","unstructured":"Finucane FM. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant. Med Hypotheses. 2018, 114:11-2. 10.1016\/j.mehy.2018.02.025","journal-title":"Med Hypotheses"},{"key":"ref5","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2020","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls Publishing, Treasure Island (FL); 2020."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5811%2Fcpcem.2020.2.45904","article-title":"Euglycemic diabetic ketoacidosis in concurrent very low-carbohydrate diet and sodium-glucose transporter-2 inhibitor use: a case report","volume":"4","author":"Earle M","year":"2020","unstructured":"Earle M, Ault B, Bonney C. Euglycemic diabetic ketoacidosis in concurrent very low-carbohydrate diet and sodium-glucose transporter-2 inhibitor use: a case report. Clin Pract Cases Emerg Med. 2020, 4:185. 10.5811%2Fcpcem.2020.2.45904","journal-title":"Clin Pract Cases Emerg Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman Y","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016, 22:753-62. 10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7074868","article-title":"Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis","volume":"2018","author":"Yu X","year":"2018","unstructured":"Yu X, Zhang S, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018, 2018:7074868. 10.1155\/2018\/7074868","journal-title":"Int J Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2021.12.011","article-title":"Diabetic ketoacidosis in pregnancy - case series, pathophysiology, and review of the literature","volume":"269","author":"Eshkoli T","year":"2022","unstructured":"Eshkoli T, Barski L, Faingelernt Y, Jotkowitz A, Finkel-Oron A, Schwarzfuchs D. Diabetic ketoacidosis in pregnancy - case series, pathophysiology, and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2022, 269:41-6. 10.1016\/j.ejogrb.2021.12.011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","author":"Scheen AJ","year":"2015","unstructured":"Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015, 54:691-708. 10.1007\/s40262-015-0264-4","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero A","year":"2018","unstructured":"Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018, 14:1287-302. 10.1080\/17425255.2018.1551877","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen AJ","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014, 53:213-25. 10.1007\/s40262-013-0126-x","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","volume":"130","author":"Tahara A","year":"2016","unstructured":"Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016, 130:159-69. 10.1016\/j.jphs.2016.02.003","journal-title":"J Pharmacol Sci"},{"key":"ref14","article-title":"SGLT2 inhibitors for type 2 diabetes mellitus treatment","volume":"32","author":"Plodkowski RA","year":"2015","unstructured":"Plodkowski RA, McGarvey ME, Huribal HM, Reisinger-Kindle K, Kramer B, Solomon M, Nguyen QT. SGLT2 inhibitors for type 2 diabetes mellitus treatment. Fed Pract. 2015, 32:8S-15S.","journal-title":"Fed Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337%2Fdc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi AE","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009, 32:1335-43. 10.2337%2Fdc09-9032","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne T","year":"2019","unstructured":"Danne T, Garg S, Peters AL, et al.. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019, 42:1147-54. 10.2337\/dc18-2316","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-017-1018-6","article-title":"Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery","volume":"65","author":"Lau A","year":"2018","unstructured":"Lau A, Bruce S, Wang E, Ree R, Rondi K, Chau A. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery. Can J Anaesth. 2018, 65:188-93. 10.1007\/s12630-017-1018-6","journal-title":"Can J Anaesth"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1089\/pancan.2018.0016","article-title":"Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace DJ","year":"2018","unstructured":"Pace DJ, Dukleska K, Phillips S, Gleason V, Yeo CJ. Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy. J Pancreat Cancer. 2018, 4:95-9. 10.1089\/pancan.2018.0016","journal-title":"J Pancreat Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4101975","article-title":"Euglycemic diabetic ketoacidosis after discontinuing SGLT2 inhibitor","volume":"2022","author":"Alhemeiri M","year":"2022","unstructured":"Alhemeiri M, Alseddeeqi E. Euglycemic diabetic ketoacidosis after discontinuing SGLT2 inhibitor. Case Rep Endocrinol. 2022, 2022:4101975. 10.1155\/2022\/4101975","journal-title":"Case Rep Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177%2F2324709617710040","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","author":"Pujara S","year":"2017","unstructured":"Pujara S, Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep. 2017, 5:10.1177%2F2324709617710040","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6089","article-title":"Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis","volume":"11","author":"Iqbal I","year":"2019","unstructured":"Iqbal I, Hamid M, Khan MA, Kainat A, Tariq S. Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis. Cureus. 2019, 11:e6089. 10.7759\/cureus.6089","journal-title":"Cureus"},{"key":"ref22","unstructured":"European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. (2016). Accessed. 02-11-2016: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2-inhibitors."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0277-0","article-title":"Practical approach to initiating SGLT2 inhibitors in type 2 diabetes","volume":"8","author":"Gomez-Peralta F","year":"2017","unstructured":"Gomez-Peralta F, Abreu C, Lecube A, et al.. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Ther. 2017, 8:953-62. 10.1007\/s13300-017-0277-0","journal-title":"Diabetes Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05666-w","article-title":"When therapeutic drugs lead to diabetes","volume":"65","author":"F\u00e8ve B","year":"2022","unstructured":"F\u00e8ve B, Scheen AJ. When therapeutic drugs lead to diabetes. Diabetologia. 2022, 65:751-62. 10.1007\/s00125-022-05666-w","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1799","article-title":"Diabetic ketoacidosis associated with cocaine use","volume":"158","author":"Warner EA","year":"1998","unstructured":"Warner EA, Greene GS, Buchsbaum MS, Cooper DS, Robinson BE. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med. 1998, 158:1799-802. 10.1001\/archinte.158.16.1799","journal-title":"Arch Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.24911\/ejmcr\/173-1622061632","article-title":"A case report of sodium glucose co-transporter 2 inhibitor associated euglycemic diabetic ketoacidosis: a diagnostic","volume":"6","author":"Richardson A","year":"2022","unstructured":"Richardson A, Vincent C. A case report of sodium glucose co-transporter 2 inhibitor associated euglycemic diabetic ketoacidosis: a diagnostic. Eur J Med Case Rep. 2022, 6:11-6. 10.24911\/ejmcr\/173-1622061632","journal-title":"Eur J Med Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115109-a-literature-review-of-the-therapeutic-perspectives-of-sodium-glucose-cotransporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:24Z","timestamp":1707508104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115109-a-literature-review-of-the-therapeutic-perspectives-of-sodium-glucose-cotransporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.29652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}